Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting
- Written by PR Newswire
SYDNEY, Aug. 3, 2023 /PRNewswire/ -- Arbele, a clinical-stage biotechnology company developing novel immunotherapies targeted for advanced gastrointestinal cancers, presented early safety data from its first-in-class CDH17xCD3 bispecific T-cell engager antibody, ARB202, at the ASCO Breakthrough conference in Yokohama, Japan.
Preliminary data from...